NCT05667493Phase 3Enrolling by invitation

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Study sponsor: Ionis Pharmaceuticals, Inc. · IONS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-08Estimated
Enrollment · participants1400Estimated
Source updated2026-04-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview